Molecular Formula | C34H38O13 |
Molar Mass | 654.66 |
Density | 1.45 |
Melting Point | 120-122℃ |
Boling Point | 800.8±65.0 °C(Predicted) |
pKa | 11.57±0.70(Predicted) |
Storage Condition | -20℃ |
In vitro study | Silvestrol is a specific eIF4A-targeting translation inhibitor. Silvestrol exhibits significant cytotoxic activity against many human cancer cell lines, such as lung, prostate, and breast cancer with IC 50 values ranging from 1 to 7 nM. Silvestrol significantly reduces the number of LNCaP cell colonies. Silvestrol (30 nM, 120 nM) induces apoptosis in LNCaP cells, through the mitochondrial pathway. Apaf-1, Caspase-2, caspase-9, and caspase-10 are involved in Silvestrol-induced apoptosis but caspase-3 and 7 are not. Silvestrol induces caspase-3 activation and apoptotic cell death in a time- and dose-dependent manner. Silvestrol-mediated cell death is attenuated in ATG7-null mouse embryonic fibroblasts (MEFs) lacking a functional autophagy protein. Silvestrol (50 nM) exerts an immediate inhibitory effect and causes near-static cell index compared with the control cells. Silvestrol (6.25 nM) enhances proliferation more than the vehicle control-treated cells, whereas a higher concentration of Silvestrol (50 nM) can inhibit cell proliferation. Silvestrol and episilvestrol display synergistic effects in combination with CDDP. |
In vivo study | Silvestrol (1.5 mg/kg, i.p.) does not adversely affect production of human IgG by xenografted B-lymphocytes in mice. Silvestrol significantly prolongs survival compared to vehicle. There is no such lymphocyte infiltration detected in the spleens of any of the Silvestrol-treated mice, and nor do these animals exhibit any other obvious signs of lymphoma upon necropsy. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.528 ml | 7.638 ml | 15.275 ml |
5 mM | 0.306 ml | 1.528 ml | 3.055 ml |
10 mM | 0.153 ml | 0.764 ml | 1.528 ml |
5 mM | 0.031 ml | 0.153 ml | 0.306 ml |
Biological activity | Silvestrol is an inhibitor of eukaryotic translation initiation factor (eIF4A) isolated from fruits and branches of Aglaia foveolata. Silvestrol induces autophagy and caspase-mediated apoptosis. |
target | eIF4A |
in vitro study | Silvestrol is a specific eIF4A-targeting translation inhibitor. Silvestrol exhibits significant cytotoxic activity against many human cancer cell lines, such as lung, prostate, and breast cancer with IC 50 values ranging from 1 to 7 nM. Silvestrol significantly reduces the number of LNCaP cell colonies. Silvestrol (30 nM, 120 nM) induces apoptosis in LNCaP cells, through the mitochondrial pathway. Apaf-1, Caspase-2, caspase-9, and caspase-10 are involved in Silvestrol-induced apoptosis but caspase-3 and 7 are not. Silvestrol induces caspase-3 activation and apoptotic cell death in a time- and dose-dependent banner. Silvestrol-mediated cell death is attenuated in ATG7-null mouse embryonic fibroblasts (MEFs) lacking a functional autophagy protein. Silvestrol (50 nM) exerts an immediate inhibitory effect and cause near-static cell index compared with the control cells. Silvestrol (6.25 nM) enhances proliferation more than the vehicle control-treated cells, whereas a higher concentration of Silvestrol (50 nM) can inhibit cell proliferation. Silvestrol and episilvestrol display synergistic effects in combination with CDDP. |
in vivo study | Silvestrol (1.5 mg/kg, I. p.) does not adversely effect production of human IgG by xenografted B- lymphocytes in mice. Silvestrol significantly prolongs survival compared to vehicle. There is no such lymphocyte infiltration detected in the spleens of any of the Silvestrol-treated mice, and nor do these animals exhibit any other obvious signs of lymphoma upon necropsy. |